PSTV
Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.
Plus Therapeutics Inc (PSTV) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | C (2.3) | D- (1.1) | C (2.4) | C- (1.9) | C- (2.1) |
| 2026-08-04 | C+ (2.7) | C (2.3) | D- (1.1) | C (2.4) | C- (1.9) | C- (2.1) |
| 2026-08-03 | C+ (2.7) | C (2.4) | D+ (1.6) | C (2.4) | C- (2.0) | C (2.2) |
| 2026-08-02 | C+ (2.7) | C (2.4) | D+ (1.6) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-07-29 | C+ (2.7) | C (2.4) | C+ (2.5) | F (0.6) | D+ (1.5) | C- (2.0) |